HF Best Ideas
AnalysesQuarterly LettersWarren AI
All funds

Jacob Funds

Sep 2025 → Jul 2026 · Publishes monthly · 2 funds

Our archive holds 3 letters from Jacob Funds, behind 11 investment theses and positions in 7 companies. Every quote below is copied verbatim from the letter it came from.

Jacob Funds’s own letters page
3
Letters
7
Companies
8
Moves
11
Theses

What they bought and sold · 8 moves

  • AddedSecuritize
    July 2026
    “The Jacob Internet Fund added one new position in the quarter, Securitize.”
    Read the letter
  • AddedKyverna Therapeutics
    July 2026
    “The Jacob Discovery Fund also added a position in Securitize in the quarter as well as a new position in Kyverna Therapeutics.”
    Read the letter
  • New positionRobinhood
    April 2026
    “The Jacob Internet Fund added four new positions in the quarter, Circle Internet Group, CrowdStrike, Reddit and Robinhood.”
    Read the letter
  • New positionReddit
    April 2026
    “The Jacob Internet Fund added four new positions in the quarter, Circle Internet Group, CrowdStrike, Reddit and Robinhood.”
    Read the letter
  • New positionCircle Internet Group
    April 2026
    “The Jacob Internet Fund added four new positions in the quarter, Circle Internet Group, CrowdStrike, Reddit and Robinhood.”
    Read the letter
  • New positionVir Biotechnology
    April 2026
    “The Jacob Small Cap Growth Fund also added a position in Circle Internet Group, as well as Vir Biotechnology.”
    Read the letter
  • New positionEnergous
    April 2026
    “The Jacob Discovery Fund added one new position in the quarter, Energous.”
    Read the letter
  • New positionCrowdStrike
    April 2026
    “The Jacob Internet Fund added four new positions in the quarter, Circle Internet Group, CrowdStrike, Reddit and Robinhood.”
    Read the letter

Companies held · 7

Every company Jacob Funds has disclosed a position in across our archive, with the letter that last mentioned it.

Theses · 11

  • Kyverna Therapeutics
    July 2026

    Kyverna Therapeutics is developing cell therapies for autoimmune diseases, with early data in stiff person syndrome and platform potential across larger indications.

    Read the full thesis
  • Securitize
    July 2026

    Securitize is a tokenization company with major partnerships, rapid asset growth, and a strong regulatory moat.

    Read the full thesis
  • Vir Biotechnology
    April 2026

    Vir Biotechnology is developing masked BiTE immunotherapies with potentially better efficacy and lower toxicity, backed by collaboration funding.

    Read the full thesis
  • Robinhood
    April 2026

    Robinhood is a consumer fintech platform whose expanding services and new initiatives could turn it into a broader financial super-app.

    Read the full thesis
  • Circle Internet Group
    April 2026

    Circle Internet Group is a stablecoin and blockchain payments platform that benefits from rapid USDC growth and a potential adoption inflection point.

    Read the full thesis
  • Reddit
    April 2026

    Reddit is a user-generated community platform with strong engagement, improving ad monetization, and growing data value for AI partnerships.

    Read the full thesis
  • CrowdStrike
    April 2026

    CrowdStrike is a cloud-native cybersecurity leader positioned to secure autonomous AI agents and enterprise adoption of agentic AI.

    Read the full thesis
  • Bed Bath & Beyond
    September 2025

    Bed Bath & Beyond is an intriguing investment opportunity due to its stake in the tZERO exchange, management restructuring efforts, potential asset sales, and a refocused retail strategy emphasizing online operations and private-label brands.

    Read the full thesis
  • Circle Internet Group
    September 2025

    Circle Internet Group is a growing digital financial infrastructure provider and the issuer of USDC, the second-largest stablecoin, which benefits from regulatory support and partnerships that enhance its market position.

    Read the full thesis
  • Inogen Inc.
    September 2025

    Inogen is stabilizing its business with strong management and a dominant market share in portable oxygen concentrators, poised for growth amid an aging population.

    Read the full thesis
  • Omeros
    September 2025

    Omeros is a biotechnology company focused on complement-related diseases, with a promising monoclonal antibody, Narsoplimab, awaiting FDA approval for a serious clotting disorder, and is in talks for a potential partnership to strengthen its financial position.

    Read the full thesis

Letter archive · 3

2026

2025

Funds · 2

  • Jacob Funds Management2
  • Jacob Funds1

Get Jacob Funds’s next letter the day it lands

We track Jacob Funds alongside hundreds of other managers, read every letter, and pull out what they bought and sold. Warren AI reads the whole archive for you.

View plans→
Share this fund